Covid-19 crisis: Glenmark claims 'clinical cure in 4 days' in Phase-3 trial

Firm claims trial results showed 28.6% faster viral clearance in overall population, says drug well tolerated with no major side effects

Amidst controversy over the pricing and efficacy of the generic oral antiviral drug favipiravir, Glenmark Pharmaceuticals announced the top line results from a Phase 3 clinical trial of the drug in mild to moderate Covid-19 patients conducted across seven clinical sites in India.

Glenmark claimed that 69.8 per cent of patients in the favipiravir treatment arm achieved ‘clinical cure’ by Day 4, which was statistically significant, compared to 44.9 per cent observed in the control arm.

The open-label, randomised, multicentre clinical trial, conducted on 150 patients, evaluated the efficacy and safety of favipiravir plus standard supportive care (favipiravir treatment arm) versus standard